NCT04553692 2025-03-28Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersIGM Biosciences, Inc.Phase 1 Terminated272 enrolled
NCT01428427 2017-11-13Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid TumorsGlaxoSmithKlinePhase 1 Completed31 enrolled
NCT00477035 2017-01-11Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic MalignanciesStanford UniversityPhase 1 Completed22 enrolled
NCT00410982 2016-06-03Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid MalignanciesM.D. Anderson Cancer CenterPhase 1 Completed145 enrolled
NCT00293345 2013-09-303-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaNational Cancer Institute (NCI)Phase 1 Completed30 enrolled
NCT00324597 2013-09-17AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaNational Cancer Institute (NCI)Phase 1 Unknown18 enrolled
NCT00019513 2012-03-23Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed108 enrolled